GlassScriptPhysician profile
Robert Michael Parsons
NPI 1588625081
$118,639.46
in general payments reported to CMS, 2019-2025
28 companies · $69K in 2025
The $69K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,886 · 2022: $15K · 2023: $13K · 2024: $14K · 2025: $69K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $59K · Travel and Lodging: $15K · Consulting Fee: $11K · Food and Beverage: $11K · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $58,710.00 |
| Travel and Lodging | $15,325.03 |
| Consulting Fee | $11,440.00 |
| Food and Beverage | $11,436.12 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $79,576.02 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $27,064.47 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $2,634.14 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $2,125.02 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,644.05 | 2021-2025 | Caplyta |
| Lundbeck LLC | $1,298.23 | 2021-2025 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $705.32 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $655.15 | 2021-2025 | Invega Sustenna, Spravato, Invega |
| Vanda Pharmaceuticals INC. | $591.27 | 2021-2025 | Fanapt |
| Neurocrine Biosciences, INC. | $560.69 | 2021-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $370.29 | 2021-2025 | Trintellix |
| Almatica Pharma LLC | $210.21 | 2021-2024 | Loreev Xr, Sertraline Hcl, Gralise |
| Sunovion Pharmaceuticals INC. | $152.78 | 2021-2022 | |
| Axsome Therapeutics, INC. | $146.36 | 2023-2024 | Auvelity, Sunosi |
| Supernus Pharmaceuticals, INC. | $137.46 | 2023-2025 | Qelbree, Qelbree |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $136.62 | 2023-2025 | Dyanavel Xr |
| Corium, LLC | $135.13 | 2022-2023 | Azstarys |
| Noven Therapeutics, LLC | $132.93 | 2021-2023 | Secuado, Xelstrym |
| Idorsia Pharmaceuticals US INC | $83.32 | 2023 | Quviviq |
| Eisai INC. | $68.83 | 2021 | |
| Avanir Pharmaceuticals, INC. | $65.08 | 2021 | |
| Indivior INC. | $54.39 | 2021 | |
| Merck Sharp & Dohme LLC | $20.24 | 2023 | Belsomra |
| Sage Therapeutics, LLC | $18.60 | 2024 | |
| Collegium Pharmaceutical, INC. | $15.04 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $13.64 | 2021 | |
| Ironshore Pharmaceuticals INC. | $12.54 | 2021 | |
| Orexo US, INC. | $11.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Parsons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.